Iloperidone: A new drug for the treatment of schizophrenia

American Journal of Health-System Pharmacy

Volumn 68, Issue 4, 2011, Pages 301-308

  Arif, Sally A ^a   Mitchell, Melissa M ^b  

^a MIDWESTERN UNIVERSITY   (United States)

^b Riverside County Regional Medical Center   (United States)

Author keywords

Absorption; Antipsychotic agents; Dosage; Drugs, availability; Iloperidone; Mechanism of action; Pharmacogenetics; Pharmacokinetics; Schizophrenia; Toxicity

Indexed keywords

FLUOXETINE; HALOPERIDOL; ILOPERIDONE; ITRACONAZOLE; KETOCONAZOLE; PALIPERIDONE; PAROXETINE; RISPERIDONE; ZIPRASIDONE;

ADULT; AKATHISIA; ANXIETY; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; DISEASE ASSOCIATION; DISEASE SEVERITY; DIZZINESS; DRUG ABSORPTION; DRUG BIOAVAILABILITY; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DYSTONIA; EXTRAPYRAMIDAL SYMPTOM; FATIGUE; FOOD AND DRUG ADMINISTRATION; GENETIC POLYMORPHISM; GLUCOSE BLOOD LEVEL; HEART PALPITATION; HUMAN; HYPERPROLACTINEMIA; INSOMNIA; LIPID BLOOD LEVEL; NOSE CONGESTION; ORTHOSTATIC HYPOTENSION; PARKINSONISM; PHARMACOGENOMICS; POSITIVE AND NEGATIVE SYNDROME SCALE; PRIORITY JOURNAL; QT PROLONGATION; REVIEW; RISK ASSESSMENT; SCHIZOPHRENIA; SIDE EFFECT; SOMNOLENCE; TACHYCARDIA; TARDIVE DYSKINESIA; WEIGHT GAIN; XEROSTOMIA;

EID: 79955980924     PISSN: 10792082     EISSN: 15352900     Source Type: Journal    
DOI: 10.2146/ajhp100079     Document Type: Review

References (38)

1. Regier DA, Narrow WE, Rae DS et al. The de facto U.S. mental and addictive disorders service system: epidemiologic catchment area prospective 1-year prevalence rates of disorders and services. Arch Gen Psychiatry. 1993; 50:85-94. (Pubitemid 23059313)
2. Diagnostic and statistical manual of mental disorders, fourth edition - text revision. Washington, DC: American Psychiatric Association; 2000.
3. Freedman R. Schizophrenia. N Engl J Med. 2003; 349:1738-49.
4. Lieberman JA, Stroup TS, McEvoy JP et al. Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med. 2005; 353:1209-23. [Erratum, N Engl J Med. 2010; 363:1092-3.]
5. Citrome L. Iloperidone for schizophrenia: a review of the efficacy and safety profile for this newly commercialised second-generation antipsychotic. Int J Clin Pract. 2009; 63:1237-48.
6. Food and Drug Administration. FDA approves Fanapt to treat schizophrenia. www.fda.gov/NewsEvents/newsroom/PressAnnouncements/ucm149578 (accessed 2010 Nov 3).
7. Albers LJ, Musenga A, Raggi MA. Iloperidone: a new benzisoxazole atypical antipsychotic drug. Is it novel enough to impact the crowded atypical antipsychotic market? Expert Opin Investig Drugs. 2008; 17:61-75.
8. Bondy B, Spellmann I. Pharmacogenetics of antipsychotics: useful for the clinician? Curr Opin Psychiatry. 2007; 20:126-30.
9. Sainati SM, Hubbard JW, Chi E et al. Safety, tolerability, and effect of food on the pharmacokinetics of iloperidone (HP 873), a potential atypical antipsychotic. J Clin Pharmacol. 1995; 35:713-20. [Erratum, J Clin Pharmacol. 1996; 36:92.]
10. Jain KK. An assessment of iloperidone for the treatment of schizophrenia. Expert Opin Investig Drugs. 2000; 9:2935-43.
11. Subramaian N, Kalkman HO. Receptor profile of P88-8991 and P95-12113, metabolites of the novel antipsychotic iloperidone. Prog Neuropsychopharmacol Biol Psychiatry. 2002; 26:553-60. (Pubitemid 34252950)
12. Mortimer AM. Novel antipsychotics in schizophrenia. Expert Opin Investig Drugs. 2004; 13:315-29. (Pubitemid 38489523)
13. Kelleher JP, Centorrino F, Albert MJ et al. Advances in atypical antipsychotics for the treatment of schizophrenia: new formulations and new agents. CNS Drugs. 2002; 16:249-61. (Pubitemid 34492932)
14. Richelson E, Souder T. Binding of antipsychotic drugs to human brain receptors: focus on newer generation compounds. Life Sci. 2000; 68:29-39.
15. Kalkman HO, Feuerbach D, Lotscher E et al. Functional characterization of the novel antipsychotic iloperidone at human D2, D3, alpha2C, 5-HT6, and 5-HT1A receptors. Life Sci. 2003; 73:1151-9.
16. Kalkman HO, Subramanian N, Hoyer D. Extended radioligand binding profile of iloperidone: a broad spectrum dopamine/ serotonin/norepinephrine receptor antagonist for the management of psychotic disorders. Neuropsychopharmacology. 2001; 25:904-14. (Pubitemid 34031895)
17. Bishara D, Taylor D. Upcoming agents for the treatment of schizophrenia. Drugs. 2008; 68:2269-92.
18. Fanapt (iloperidone) package insert. Rockville, MD: Vanda Pharmaceuticals; 2009.
19. Ehret MJ, Sopko MA, Levine A. Iloperidone: a novel atypical antipsychotic for the treatment of schizophrenia. Formulary. 2008; 43:190-2,194-6,203.
20. Nnadi CU, Malhotra AK. Individualizing antipsychotic drug therapy in schizo phrenia: the promise of pharmacogenetics. Curr Psychiatry Rep. 2007; 9:313-8. (Pubitemid 47490003)
21. Nnadi CU, Malhotra AK. Clinical and pharmacogenetic studies of iloperidone. Per Med. 2008; 5:367-75.
22. Mutlib AE, Strupczewski JT, Chesson SM. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone. Drug Metab Dispos. 1995; 23:951-64.
23. Lavedan C, Volpi S, Polymeropoulos MH et al. Effect of a ciliary neurotrophic factor polymorphism on schizophrenia symptom improvement in an iloperidone clinical trial. Pharmacogenomics. 2008; 9:289-301. (Pubitemid 351816766)
24. Borison RL, Huff FJ, Griffiths L et al. Ef- ficacy of 4 mg/day and 8 mg/day iloperidone (HP 873) administered to schizophrenic patients for 42 days. Psychopharmacol Bull. 1996; 32:416. Abstract.
25. Corbett R, Griffiths L, Shipley JE et al. Iloperidone: preclinical profile and early clinical evaluation. CNS Drug Rev. 1997; 3:120-47. (Pubitemid 27509410)
26. Mucke HA, Castaner J. Iloperidone. Drug Future. 2000; 25:29-40.
27. Potkin SG, Litman RE, Torres R et al. Efficacy of iloperidone in the treatment of schizophrenia: initial phase 3 studies. J Clin Psychopharmacol. 2008; 28(suppl 1):S4-11.
28. Sacristán JA, Gomez J, Montejo A et al. Doses of olanzapine, risperidone, and haloperidol used in clinical practice: results of a prospective pharmacoepidemiologic study. Clin Ther. 2000; 22:583-99. (Pubitemid 30434311)
29. Cutler AJ, Kalali AH, Weiden PJ et al. Four-week, double-blind, placebo- and ziprasidone-controlled trial of iloperidone in patients with acute exacerbations of schizophrenia. J Clin Psychopharmacol. 2008; 28(suppl 1):S20-8.
30. Kane JM, Lauriello J, Laska E et al. Longterm efficacy and safety of iloperidone: results from 3 clinical trials for the treatment of schizophrenia. J Clin Psychopharmacol. 2008; 28(suppl 1):S29-35.
31. Weiden PJ, Cutler AJ, Polymeropoulos MH et al. Safety profile of iloperidone: a pooled analysis of 6-week acute-phase pivitol trials. J Clin Psychopharmacol. 2008; 28(suppl 1):S12-9.
32. Lauriello J, Torres R, Wolfgang CD et al. Extrapyramidal symptom and akathisia profile of iloperidone in schizophrenia clinical trials. Paper presented at 161st Annual Meeting of the American Psychiatric Association. Washington, DC; 2008 May.
33. Chouinard G, Margolese HC. Manual for the Extrapyramidal Symptom Rating Scale (ESRS). Schizophr Res. 2005; 76:247-65. (Pubitemid 40804771)
34. Barnes TR. A rating scale for drug-induced akathisia. Br J Psychiatry. 1989; 154:672-6. (Pubitemid 19154942)
35. Weiden P, Wolfgang C, Baroldi P. Changes in akathisia with iloperidone, risperidone, or placebo over the course of an acute efficacy trial. Paper presented at the 160st Annual Meeting of the American Psychiatric Association. San Diego, CA; 2007 May.
36. Worrel JA, Marken PA, Beckman SE et al. Atypical antipsychotic agents: a critical review. Am J Health-Syst Pharm. 2000; 57:238-55.
37. Kane JM. Review of treatments that can ameliorate nonadherence in patients with schizophrenia. J Clin Psychiatry. 2006; 67(suppl 5):S9-14.
38. Hill CL, Phadke D, Boyce KM. Fourweek iloperidone depot injectable: safety and pharmacokinetic profile in patients with schizophrenia and schizoaffective disorder. Paper presented at the 161st Annual Meeting of the American Psychiatric Association. Washington, DC; 2008 May.